Special Issue "Recent Advances in Antifungal Drugs (Volume II)"

Dear Colleagues,

The arsenal of antifungal agents against fungal diseases is limited. Furthermore, most treatments are associated with side effects, drug interactions, harmful risks for pregnant women, or fungal resistance.

The high burden and increasing prevalence of both invasive and superficial fungal infections, associated with biofilm formation, toxicity, interactions related to current antifungals, as well as increased resistance, require the development of new antifungals—preferably with a new form of action. Additionally, the availability of oral alternatives or mode drug use would allow outpatient treatment, resulting in greater patient comfort and therapy adherence. Besides, when needed due to immunosuppression, associated therapies should also focus on further research.

Antifungals are clinically available to treat fungal infections, and primarily target ergosterol in the fungal cell membrane or 1,3-β-D-glucan in the fungal cell wall. These classes include polyenes, triazoles, and echinocandins. Although the newer antifungals and the improved formulations of others have advanced, our ability to treat patients with fungal infections is often limited by toxicity, drug interactions, and the need for intravenous administration in the case of systemic mycoses.

Therefore, this Special Issue intends to receive manuscripts that present advances in antifungals, new targets, new formulations that utilize novel delivery systems to enhance treatment efficacy and compliance, and new strategies to treat fungal infections.

Prof. Dr. Maria José Soares Mendes Giannini
Dr. Luigi Scipione
Dr. Marcia S.C. Melhem
Dr. Ana Marisa Fusco Almeida
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• antifungal drugs
• resistance
• biofilms resistance
• new targets
• invasive fungal infections
• superficial infections
• pipeline
• new formulations
• treatment

• Recent Advances in Antifungal Drugs in Pharmaceutics (11 articles)